MetadataShow full item record
AbstractThe nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic.
PublisherPublic Library of Science
- The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.
- Authors: McMullan LK, Flint M, Dyall J, Albariño C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF
- Issue date: 2016 Jan
- Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial.
- Authors: Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquoi T, Gandi R, Joseph S, Osman HK, Brooks TJ, Simpson AJ, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Pardinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW, RAPIDE-TKM trial team.
- Issue date: 2016 Apr
- Current status of chemically synthesized inhibitors of Ebola virus.
- Authors: Cardile AP, Mayers DL, Bavari S
- Issue date: 2014
- Treatment of ebola virus disease.
- Authors: Kilgore PE, Grabenstein JD, Salim AM, Rybak M
- Issue date: 2015 Jan
- Trial design for evaluating novel treatments during an outbreak of an infectious disease.
- Authors: Whitehead J, Olliaro P, Lang T, Horby P
- Issue date: 2016 Feb